Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB) News provided by. Norgine Jul 08, 2025, 8:01 AM ET IFINWIL ® ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants ...

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing ...

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants ...

By collaborating with international regulatory partners through Project Orbis, we are advancing our strategy to broaden ...